Source comparison
CJC-1295 vs Ipamorelin: Distinct Roles in the Stack
The CJC-1295 vs Ipamorelin distinction matters because these compounds do fundamentally different things. Researchers occasionally ask which one is “better” — but the framing is wrong. CJC-1295 amplifies pulse amplitude by loading the somatotroph GH pool. Ipam
This comparison does not assign a generated winner or score.
- The CJC-1295 vs Ipamorelin distinction matters because these compounds do fundamentally different things. Researchers occasionally ask which one is “better” — but the framing is wrong. CJC-1295 amplifies pulse amplitude by loading the somatotroph GH pool. Ipamorelin controls pulse frequency and timing through exocytosis. Used alone, each addresses only half of the somatotropic axis; used together, they engage both.
- Receptor Target
- GHRH receptor on somatotrophs
- Ghrelin/GHS-R1a receptor on pituitary
- Role in GH Release
- Amplifies pulse amplitude
- Increases pulse frequency
- Cortisol Impact
- Minimal
- None documented at research doses
- Prolactin Impact
- Appetite Stimulation
- None
- Minimal (unlike GHRP-6)
- Research Half-Life
- ~30 min (no DAC) / 6–8 days (DAC)
- ~2 hours
- Published data suggests the combined stack can produce GH elevations 2–3× greater than either compound administered alone. The combination also preserves natural negative feedback through somatostatin — meaning GH cannot rise uncontrollably, a safety feature absent with exogenous HGH.